- Home
- CIVB vs AVIR Comparison
CIVB vs AVIR Comparison
Compare CIVB & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIVB | AVIR |
|---|---|---|
| Founded | 1884 | 2012 |
| Country | United States | United States |
| Employees | 535 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.0M | 434.5M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CIVB | AVIR |
|---|---|---|
| Price | $27.42 | $4.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $26.60 | $10.00 |
| AVG Volume (30 Days) | 84.2K | ★ 263.7K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 31.34 | 3.00 |
| EPS | ★ 0.72 | N/A |
| Revenue | $19,023,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $14.88 | N/A |
| Revenue Next Year | $5.99 | N/A |
| P/E Ratio | $37.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.95 | $2.78 |
| 52 Week High | $27.48 | $6.45 |
Technical Indicators
Market Signals| Indicator | CIVB | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 65.12 | 49.33 |
| Support Level | $21.39 | $4.10 |
| Resistance Level | $27.48 | $4.59 |
| Average True Range (ATR) | 0.62 | 0.18 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 96.99 | 81.18 |
Price Performance
Historical ComparisonAbout CIVB Civista Bancshares Inc.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.